# Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary

> **NCT04429321** · PHASE1 · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 1 (actual)

## Conditions studied

- Renal Cell Carcinoma
- Renal Cell Carcinoma Stage IV

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DEVICE:** bland embolization

## Key facts

- **NCT ID:** NCT04429321
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-26
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** failure to accrue
- **Last updated:** 2024-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04429321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04429321, "Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04429321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*